Clinical Trial Update: Safety of Locally Delivered Allogeneic Mesenchymal Stromal Cells [Phase 1]

View source ↗

Summary

A Phase 1 clinical trial evaluated the safety of locally delivered allogeneic mesenchymal stromal cells for corneal defects. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Corneal Defect

Drugs mentioned

• Allogeneic Mesenchymal Stromal Cells (mesenchymal stromal cells)

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Mesenchymal Stromal Cells, Cornea | Phase 1 | Status: COMPLETED